The RESTORE Randomized Controlled Trial: Impact of a Multidisciplinary Rehabilitative Program on Cardiorespiratory Fitness in Esophagogastric Cancer Survivorship: Erratum

In the November 2018 issue of Annals of Surgery in the article by O’Neill et al, “The RESTORE Randomized Controlled Trial: Impact of a Multidisciplinary Rehabilitative Program on Cardiorespiratory Fitness in Esophagogastric cancer Survivorship,” it was reported that, of the participants in the intervention group, 8 had cancer located in the esophagus and 12 had cancer located in the esophago-gastric junction, but this should have been reported as 9 had cancer located in the esophagus and 11 had cancer located in the esophago-gastric junction. These data have been corrected in the table below. TABLE 2 - Demographic Characteristics of Participants Control (N=22) Intervention (N=21) Mean/Median/ Frequency (Standard Deviation)/(IQR)/(%) Mean /Median Frequency (Standard Deviation)/ (IQR)/(%) P Sex Male 18 (81.8) 17 (81.0) 1.000 Female 4 (18.2) 4 (19.0) Age, yr 64.14 (10.46) 67.19 (7.49) 0.280 BMI, kg/m2 25.67 (4.83) 25.69 (4.02) 0.989 Baseline VO2peak, mL–1 × min–1 × kg–1 21.75 (4.49) 18.73 (4.07) 0.026* Baseline fitness category Very poor 13 (59.1) 14 (66.7) 0.843 Poor/fair 9 (40.9) 7 (33.3) Baseline physical activity Sedentary time, min/wk 3773.50 (975.25) 3449.00 (1511.00) 0.586 Light activity, min/wk 1655.73 (648.32) 1491.57 (473.16) 0.471 MVPA, min/wk 136.00 (136.75) 132.00 (280.50) 0.427 Time postsurgery, mo 33.68 (19.56) 23.52 (15.23) 0.065 Histological type of tumor Adenocarcinoma 19 (86.4) 14 (66.7) N/A Squamous cell carcinoma 2 (9.1) 6 (28.6) Associated Barrett 1 (4.5) 1 (4.8) Tumor location Esophagus 4 (18.2) 9 (42.9) N/A Esophago-gastric junction 15 (68.2) 11 (52.4) Stomach 3 (13.6) 1 (4.8) Tumor classification (T) Tis 2 (9.1) 2 (9.5) N/A T1 4 (18.2) 7 (33.3) T2 4 (18.2) 2 (9.5) T3 12 (54.5) 10 (47.6) T4 0 (0.0) 0 (0.0) (N) N0 14 (63.6) 12 (57.1) N1 3 (13.6) 8 (38.1) N2 5 (22.7) 1 (4.8) (M) M0 22 (100) 21 (100) Type of surgery Transhiatal esophagectomy 5 (22.72) 8 (38.10) N/A Transthoracic esophagectomy 11 (50.00) 11 (52.40) Gastrectomy 6 (27.27) 2 (9.52) Significant postoperative complications (Clavien Dindo ≥3) Yes 8 (36.4) 6 (28.6) 0.747 No 14 (63.6) 15 (71.4) Neoadjuvant treatment Yes 16 (72.7) 11 (52.4) 0.287 No 6 (27.3) 10 (47.6) Adjuvant treatment Yes 5 (22.7) 4 (19.0) 1.000 No 17 (77.3) 17 (81.0) Barrett’s esophagus Yes 14 (63.6) 12 (57.1) 0.902 No 8 (36.4) 9 (42.9) Cardiac history Yes 1 (4.5) 3 (14.3) 0.345 No 21 (95.5) 18 (85.7) Respiratory history Yes 4 (18.2) 3 (14.3) 1.000 No 18 (81.8) 18 (85.7) Smoking Never 4 (18.2) 2 (9.5) N/A Current smoker 1 (4.5) 2 (9.5) Stopped >8 wk 17 (77.3) 17 (81.0) Data are presented as the mean/median (standard deviation/ IQR) for continuous variable and as frequency (percentage) for categorical variables. N/A—unable to run a statistical test to compare between groups on some categorical variables as some variables do not meet minimum criteria of 5 in a category for the Chi-squared test and Fisher exact test is only applicable for a 2×2 table.*Statistically significant difference.BMI indicates body mass index; IQR, interquartile range; M, metastases; MVPA, time spent per week in moderate-vigorous physical activity as measured by Actigraph accelerometers; N, nodes; T, tumor.